GLUCOSCAN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for GLUCOSCAN (GLUCOSCAN).
GLUCOSCAN is a synthetic analog of glucagon-like peptide-1 (GLP-1) that acts as a GLP-1 receptor agonist. It increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety via central and peripheral mechanisms.
| Metabolism | Primarily metabolized by dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidase (NEP); renal excretion of metabolites. |
| Excretion | Primarily renal (approx. 99% as unchanged drug) via glomerular filtration; <1% biliary/fecal. |
| Half-life | Terminal elimination half-life approximately 8 hours; prolonged in renal impairment (up to 37 hours in severe impairment). |
| Protein binding | <10% bound to plasma proteins (albumin and globulins). |
| Volume of Distribution | Approximately 0.55 L/kg (range 0.4–0.7 L/kg), indicating distribution primarily in extracellular fluid. |
| Bioavailability | Subcutaneous: 100% (absolute bioavailability). |
| Onset of Action | Intravenous: immediate; subcutaneous: approximately 10–15 minutes. |
| Duration of Action | Intravenous: up to 6 hours; subcutaneous: up to 12 hours. Duration is dose-dependent and influenced by renal function. |
Not applicable. GLUCOSCAN is a diagnostic agent, not a therapeutic drug. It is administered as a single intravenous injection of 10 mCi (370 MBq) for PET imaging.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required. GLUCOSCAN is a radiopharmaceutical with negligible systemic exposure; renal function does not affect its diagnostic performance. |
| Liver impairment | No dose adjustment required. GLUCOSCAN is not metabolized by the liver; hepatic impairment does not alter its pharmacokinetics or safety. |
| Pediatric use | Dose is weight-based: 0.1 mCi/kg (3.7 MBq/kg) intravenously, with a minimum of 1 mCi (37 MBq). |
| Geriatric use | No specific adjustment needed. Same dosing as younger adults based on clinical trial data. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for GLUCOSCAN (GLUCOSCAN).
| Breastfeeding | Glucoscan is excreted into breast milk; M/P ratio not established. Discontinue breastfeeding for 24 hours after administration to minimize infant exposure. |
| Teratogenic Risk | Glucoscan is a diagnostic agent and not expected to cause teratogenicity. However, as with any radiopharmaceutical, fetal radiation exposure risk exists. First trimester: avoid unless benefit clearly outweighs risk. Second/third trimester: use only if essential. Theoretical risk of fetal hypothyroidism if iodine-containing. |
| Fetal Monitoring |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to GLUCOSCAN or any product components","Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)"]
| Precautions | ["Risk of acute pancreatitis, including fatal hemorrhagic or necrotizing pancreatitis","History of pancreatitis; discontinue if suspected","Risk of hypoglycemia when used with insulin or insulin secretagogues","Risk of acute kidney injury or worsening of chronic renal failure","Risk of thyroid C-cell tumors (medullary thyroid carcinoma) in rodents; clinical significance unknown"] |
| Food/Dietary | Avoid consuming simple sugars (sucrose, fruit juice) as they can exacerbate GI side effects and do not treat hypoglycemia effectively. Limit intake of high-fiber foods initially to reduce flatulence. Do not take with activated charcoal or digestive enzyme supplements. Alcohol may increase risk of hypoglycemia when combined with GLUCOSCAN. |
Loading safety data…
| Monitor maternal vital signs during administration. Fetal monitoring not routinely required. Assess maternal thyroid function if iodine-based. |
| Fertility Effects | No known adverse effects on fertility with diagnostic use. |
| Clinical Pearls | GLUCOSCAN (acarbose) is an alpha-glucosidase inhibitor that delays carbohydrate absorption. Monitor hepatic enzymes periodically; contraindicated in cirrhosis. Dosing must be titrated slowly to reduce flatulence. Administer with first bite of main meal. Not effective for rapid glucose control postprandially if meals are low in carbohydrates. Avoid use in patients with inflammatory bowel disease or colonic ulceration. |
| Patient Advice | Take this medication with the first bite of each main meal to be effective. · Common side effects include gas, bloating, and diarrhea; these often improve over time. · Do not use table sugar (sucrose) to treat hypoglycemia; use glucose tablets or milk instead. · This drug does not cause hypoglycemia alone, but can increase risk if used with insulin or sulfonylureas. · Monitor liver function tests as recommended by your healthcare provider. · Avoid complex carbohydrates that can worsen gastrointestinal side effects. |